2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117936
    Muscarinic agonist 1 168818-83-5 98%
    Muscarinic agonist 1, AF267, functions by alleviating cognitive impairments.
    Muscarinic agonist 1
  • HY-117952
    L 743310 187724-86-3 98%
    L 743310 is a non-peptide, selective antagonist of the human neurokinin hNK1 receptor, with high affinity for primate and cloned human hNK1 receptors and lower affinity for rodent NK1 receptors. L 743310 inhibits resiniferatoxin-induced plasma protein extravasation in guinea pig esophagus. L 743310 has a dose-dependent inhibitory effect on cisplatin-induced emesis.
    L 743310
  • HY-117955
    GMA-839 162882-76-0 98%
    GMA-839 is a selective modulator of the γ-aminobutyric acid A receptor (GABAA) with an IC50 value of 230 nM. GMA-839 exhibits potent anxiolytic-like activity, demonstrating significant dose-dependent anxiolytic effects in animal models, with an effective oral dose of 1.6 mg/kg. Significant increases in punished responding were observed in squirrel monkeys and pigeons. GMA-839 shows promise for research in the field of anxiolytics.
    GMA-839
  • HY-117957
    BMS-932481 1263871-36-8 98%
    BMS-932481 is an orally active modulator for γ-secretase, selectively reduce Aβ1-42 and Aβ1-40 production, with IC50s of 6.6 and 25.3 nM, respectively.
    BMS-932481
  • HY-117979
    Alphadolone 14107-37-0 98%
    Alphadolone is a GABAA receptor positive allosteric modulator. Alphadolone has antinociceptive effects. Alphadolone causes general anaesthesia.
    Alphadolone
  • HY-117983
    RU-505 1314206-29-5 98%
    RU-505 is an effective β-amyloid (Aβ)-fibrinogen interaction inhibitor with IC50s of 5.00 and 2.72 μM in fluorescence polarization (FP) and AlphaLISA assays, respectively. RU-505 is highly permeable to the BBB. RU-505 reduces cerebral amyloid angiopathy (CAA). RU-505 can be used for the research of Alzheimer’s disease (AD).
    RU-505
  • HY-117984
    RU 35929 111711-47-8 98%
    RU 35929 is a nootropic agent. RU 35929 enhances learning and memory.
    RU 35929
  • HY-117993
    MIND4 1639965-26-6 98%
    MIND4 is a neuroprotective thiozoline compound that inhibits the deacetylase SIRT2. MIND4 is also an inducer and activator of the nuclear factor NRF2. MIND4 can induce NRF2 activation in neurons and non-neuronal cells and reduce the production of reactive oxygen and nitrogen intermediates.
    MIND4
  • HY-118008
    Lesopitron 132449-46-8 98%
    Lesopitron (E-4424) is a 5-HT receptor agonist with potent anxiolytic-like effects. Lesopitron inhibits forskolin-stimulated adenylate cyclase activity with an IC50 value of 125 nM.
    Lesopitron
  • HY-118010
    Norfenfluramine 1886-26-6 98%
    Norfenfluramine ((±)-Norfenfluramine) is a major and brain-penetrant metabolite of Fenfluramine. Norfenfluramine can interact with 5-HT transporters to release 5-HT from neurons. Norfenfluramine displays antiepileptic effects in vivo.
    Norfenfluramine
  • HY-118022
    VU0361747 1309976-66-6 98%
    VU0361747 is a potent and selective positive allosteric modulator of metabotropic glutamate receptor 4 (mGluR4 PAM). VU0361737 has neuroprotective effect. VU0361737 significantly reverses Amphetamine-induced hyperlocomotion in vivo.
    VU0361747
  • HY-118030
    RQ-00311651 1257116-00-9 98%
    RQ-00311651 is a T-type calcium channel blocker that specifically targets the Cav3.2 isoform with a role in neuropathic and visceral pain. RQ-00311651 significantly inhibits T currents in HEK293 cells expressing human Cav3.1 or Cav3.2. RQ-00311651 also inhibited high potassium-induced calcium signaling. RQ-00311651 also inhibits antiallergic properties in rats and mice with neuropathic pain induced by spinal nerve injury or Paclitaxel (HY-B0015). Oral and intraperitoneal injection (10-20 mg/kg) inhibits Cerulein (HY-A0190)-induced acute pancreatitis and cyclophosphamide-induced cystitis in mice.
    RQ-00311651
  • HY-118048
    NAV 26 1198160-14-3 99.79%
    NAV 26 (compound 26) is a selective voltage-gated sodium channel Nav1.7 blocker with an IC50 of 0.37 μM. NAV 26 can be used for pain research.
    NAV 26
  • HY-118064
    (R)-Thionisoxetine 163059-33-4 98%
    (R)-Thionisoxetine is a potent and selective inhibitor of central and peripheral norepinephrine (NE) uptake. (R)-thionisoxetine prevented hypothalamic NE depletion by 6-hydroxydopamine with an ED50 of 0.21 mg/kg. (R)-Thionisoxetine can be used for the research of a variety of diseases including depression and urinary incontinence.
    (R)-Thionisoxetine
  • HY-118072
    Aspalatone 147249-33-0 98%
    Aspalatone is an orally active antiplatelet aggregant with IC50 of 180 μM. Aspalatone has antioxidant and neuroprotective activities.
    Aspalatone
  • HY-118120
    GEMSA 77482-44-1 98%
    GEMSA is a potent inhibitor of enkephalin convertase (Ki=8.8 nM). GEMSA elicites analgesia.
    GEMSA
  • HY-118127
    Rilapine 79781-95-6 98%
    Rilapine is an atypical antipsychotic agent.
    Rilapine
  • HY-118182
    Tidembersat 175013-73-7 98%
    Tidembersat (Example 4) is a benzopyran derivative that can be used in the research of a variety of CNS disorders and traumatic brain injury.
    Tidembersat
  • HY-118200
    BRL-41992 124097-52-5 98%
    BRL-41992 is a selective α₂B-adrenergic receptor antagonist. BRL-41992 exhibits 94-fold higher selectivity for the α₂B-receptor than for the α₂A-receptor with Kᵢ values in neonatal rat lung tissue (expressing the α₂B-receptor) and in human platelet membranes (expressing the α₂A-receptor) of 1.1 and 103.3 nM. BRL-41992 can be used to verify the functional differences of α₂ receptor subtypes.
    BRL-41992
  • HY-118222
    KBR 2822 126988-60-1 98%
    KBR 2822 is an inhibitor of neurological target esterase (NTE) and has an inhibitory effect on AChE. KBR 2822 can aggravate neurological damage under certain conditions, but does not cause neurological disease when used alone in the absence of direct neurotoxicity or biochemical damage.
    KBR 2822
Cat. No. Product Name / Synonyms Application Reactivity